Skip to content

Inspection prep notes · Sterility and contamination control

Environmental monitoring

FDA looks less at whether environmental monitoring records exist than at whether the monitoring represents actual production conditions and whether recoveries were investigated through to the end. The findings below are quoted from warning letters and Form 483s.

What inspectors cited

1Monitoring did not represent actual production conditions

Your environmental monitoring program lacks adequate routine environmental monitoring that captures data representative of aseptic production conditions.

FDA Warning Letter · Pine Pharmaceuticals, LLC · 2026-10-06 · View document

Specifically, personnel monitoring, settle plates, active air sampling, or non-viable particles is not performed.

FDA 483 · Maiva Pharma Private Limited · 2026-03-06 · View document

2Personnel monitoring was not performed

Similarly, personnel monitoring samples were not collected for production and engineering personnel who worked in the aseptic processing room.

FDA Warning Letter · Rohto Pharmaceutical Co., Ltd. · 2026-10-20 · View document

You employ contractors to clean your BSCs; you no longer perform personnel monitoring of these contractors upon exiting the BSCs despite significant recoveries from these personnel uncovered during your [redacted] environmental monitoring trend report.

FDA 483 · SAFC Pharma Carlsbad · 2026-10-26 · View document

3Sampling locations and frequencies were not justified

You failed to demonstrate that the locations and frequencies established for viable air sampling, surface monitoring, and non-viable particulate sampling were adequately justified and sufficient to promptly detect contamination risks.

FDA Warning Letter · Hanlim Pharm Co., Ltd. · 2026-10-13 · View document

Your firm has not conducted a risk assessment of your facility to justify the sampling locations of your environmental monitoring nor have you identified microorganisms that may be considered objectionable.

FDA 483 · LeeSar Inc · 2026-11-05 · View document

4Results above the limits were not investigated

Your firm failed to investigate multiple action-level environmental monitoring excursions that occurred between January and June 2025 in the ISO 5 and 7 areas.

FDA Warning Letter · Jubilant HollisterStier General Partnership · 2026-06-23

Your firm has failed to adequately identify and investigate the recurring recovery of the endospore-forming microorganism Bacillus spp. during environmental and personnel monitoring activities in ISO 5, 7, and 8 classified areas.

FDA 483 · LeeSar Inc · 2026-11-05 · View document

5Recoveries were not identified and trends were not assessed

These recoveries were not formally identified, preventing your firm from conducting adequate investigations.

FDA Warning Letter · Northland Nuclear Medicine, LLC · 2026-10-27

As part your Environmental Monitoring Trending Program, you do not consider the implications of recoveries of spore forming vs. non-spore forming microorganisms in your [redacted] trend reports.

FDA 483 · SAFC Pharma Carlsbad · 2026-10-26 · View document

Questions to check against your procedures

  1. Does routine environmental monitoring capture data representative of actual aseptic production conditions?
  2. Are personnel monitoring, settle plates, active air sampling and non-viable particle counts also performed during activities such as transfer and pre-assembly?
  3. Are personnel monitoring samples collected from production and engineering personnel who worked in the aseptic processing room, and from cleaning contractors?
  4. Is there a documented risk assessment justifying the locations and frequencies for viable air, surface and non-viable particulate sampling?
  5. Is an investigation opened for every result above the action level? Does a recurring recovery of the same organism lead to identification and investigation?
  6. Are recoveries formally identified? Do trend reports consider the implications of recoveries of spore-forming microorganisms?

Compiled by AI from public findings and checked by a person. Quotations are verbatim from the original documents; (b)(4) marks text redacted in the original. As of 2026-11-15.

Weekly Newsletter

New GMP inspection findings, every Monday

Every Monday we email the week's new inspection records from the FDA, EMA, Health Canada and MFDS, with a short summary of the week's regulatory news. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.